- Home
- CMND vs PPBT Comparison
CMND vs PPBT Comparison
Compare CMND & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMND | PPBT |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.9M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CMND | PPBT |
|---|---|---|
| Price | $1.82 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 215.0K | 43.1K |
| Earning Date | 03-12-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.41 |
| 52 Week High | $4.66 | $5.18 |
Technical Indicators
Market Signals| Indicator | CMND | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 34.26 | 27.63 |
| Support Level | $1.74 | $0.60 |
| Resistance Level | $2.76 | $1.41 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 0.58 | 11.00 |
Price Performance
Historical ComparisonAbout CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.